FindTrial
Sign In

SAGE-718

DRUG11 trials

Sponsors

Supernus Pharmaceuticals, Inc.

Conditions

Alzheimer DiseaseAlzheimer's DiseaseCognitive DysfunctionHealthy VolunteerHuntington DiseaseHuntington's DiseaseMild Cognitive ImpairmentMild Dementia

Phase 1

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
CompletedNCT03770780
Supernus Pharmaceuticals, Inc.Healthy Volunteer
Start: 2018-11-12End: 2019-03-22Updated: 2025-09-17
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
CompletedNCT03771586
Supernus Pharmaceuticals, Inc.Healthy Volunteer
Start: 2018-09-24End: 2019-01-02Updated: 2025-09-17
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B
CompletedNCT03787758
Supernus Pharmaceuticals, Inc.Huntington Disease
Start: 2019-02-28End: 2019-10-07Updated: 2025-09-17
A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects
CompletedNCT03844906
Supernus Pharmaceuticals, Inc.Healthy Volunteer
Start: 2018-12-27End: 2019-04-01Updated: 2025-09-17

Phase 2

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
CompletedNCT04476017
Supernus Pharmaceuticals, Inc.Cognitive Dysfunction, Parkinson Disease
Start: 2020-07-31End: 2022-03-25Updated: 2025-09-15
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
CompletedNCT04602624
Supernus Pharmaceuticals, Inc.Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
Start: 2020-12-07End: 2021-09-28Updated: 2025-09-15
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
CompletedNCT05107128
Supernus Pharmaceuticals, Inc.Huntington's Disease
Start: 2022-01-26End: 2024-10-03Updated: 2025-09-15
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
CompletedNCT05318937
Supernus Pharmaceuticals, Inc.Cognitive Dysfunction, Parkinson Disease
Start: 2022-06-06End: 2024-02-23Updated: 2025-09-12
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
CompletedNCT05358821
Supernus Pharmaceuticals, Inc.Huntington Disease
Start: 2022-05-26End: 2024-04-10Updated: 2025-09-15
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
CompletedNCT05619692
Supernus Pharmaceuticals, Inc.Alzheimer's Disease, Mild Cognitive Impairment, Mild Dementia
Start: 2022-11-29End: 2024-07-09Updated: 2025-09-15

Phase 3

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
TerminatedNCT05655520
Supernus Pharmaceuticals, Inc.Huntington's Disease
Start: 2022-12-14End: 2025-01-20Updated: 2025-12-17

Related Papers

The Phase 2, Randomized, Placebo-controlled PRECEDENT Trial of SAGE-718 in Patients With Parkinson's Disease Cognitive Impairment: Clinical Trial in Progress (P2-11.005)
Neurology2023-04-25
SAGE‐718 in Patients With Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease: Results From the Phase 2 LUMINARY Study
Alzheimer s & Dementia2022-12-013 citations
J12 The perspective program: evaluating the effect of SAGE-718 on cognitive function in patients with Huntington’s disease
2022-09-01
SAGE-718 in Parkinson’s Disease Mild Cognitive Impairment: Results from the Phase 2 PARADIGM Study (Part A) (P10-11.004)
Neurology2022-05-03